FrancophonIA/ELRC3.0 huggingface dataset:
English: Contains glycerol, zinc oxide, dibasic sodium phosphate7H20 with m-cresol as a preservative in water for injection.
Estonian: Sisaldab glütserooli, tsinkoksiidi, dinaatriumvesinikfosfaatheptahüdraati, säilitusainena metakresooli süstevees.
English: NAME OF THE MEDICINAL PRODUCT Liprolog 100 units/ml solution for injection in cartridge Insulin lispro
Estonian: RAVIMPREPARAADI NIMETUS Liprolog 100 ühikut/ml süstelahus kolbampullis Lispro-insuliin
English: PACKAGE LEAFLET: INFORMATION FOR THE USER Liprolog 100 units/ml KwikPen, solution for injection in a pre-filled pen insulin lispro Each KwikPen delivers 1 - 60 units in steps of 1 units.
Estonian: Liprolog KwikPen 100 ühikut/ml, süstelahus pen-süstlis lispro-insuliin Iga KwikPen väljastab ühiku kaupa 1...60 ühikut
English: Insulin requirements may be increased by medicinal products with hyperglycaemic activity, such as oral contraceptives, corticosteroids, or thyroid replacement therapy, danazol, beta2 stimulants (such as ritodrine, salbutamol, terbutaline).
Estonian: Hüperglükeemilise toimega ravimite, nt suukaudsete kontratseptiivide, kortikosteroidide, kilpnäärme hormoonide asendajate, danasooli ja beeta2-retseptorite stimulaatorite (nt ritodriini, salbutamooli, terbutaliini) samaaegsel kasutamisel võib insuliinivajadus suureneda.
English: Insulin lispro
Estonian: Annuse aken
English: Injecting Liprolog
Estonian: Liprolog'i süstimine
English: Marketing Authorisation Holder and Manufacturer Liprolog Mix50 100 units/ml suspension for injection in cartridge is made by:
Estonian: Liprolog Mix50 100 ühikut/ml süstesuspensiooni kolbampullis toodab:
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Liprolog Mix25 100 units/ml suspension for injection in cartridge 25% insulin lispro and 75% insulin lispro protamine suspension Subcutaneous use
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE Liprolog Mix25 100 ühikut/ml süstesuspensioon kolbampullis 25 % lispro-insuliini ja 75 % lispro-insuliini protamiinsuspensiooni Subkutaanne
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Liprolog Mix50 100 units/ml suspension for injection in cartridge 50% insulin lispro and 50% insulin lispro protamine suspension Subcutaneous use
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE Liprolog Mix50 100 ühikut/ml süstesuspensioon kolbampullis 50 % lispro-insuliini ja 50 % lispro-insuliini protamiinsuspensiooni Subkutaanne
English: Marketing Authorisation Holder and Manufacturer Liprolog Mix25 100 units/ml suspension for injection in cartridge is made by:
Estonian: Liprolog Mix25 100 ühikut/ml süstesuspensiooni kolbampullis toodab:
English: • oral hypoglycaemics, (e.g. metformin, acarbose, sulphonylurea agents, pioglitazone,
Estonian: • suukaudseid veresuhkrut alandavaid ravimeid (nt metformiin, akarboos, sulfonüüluurea preparaadid, pioglitasoon, empagliflosiin, DPP-4-inhibiitorid nt sitagliptiin või saksagliptiin),
English: • You should also tell your doctor, pharmacist or diabetes nurse if you are planning to go abroad.
Estonian: • Kui te plaanite välismaale sõitu, siis rääkige sellest eelnevalt arstile, apteekrile või diabeediõele.
English: Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.
Estonian: Mistahes kardiaalsete sümptomite ägenemise korral tuleb ravi pioglitasooniga ära jätta.
English: • Store the Pen you are currently using at room temperature (up to 30°C) and away from dust,
Estonian: • Hoidke kasutatavat pen-süstlit toatemperatuuril (kuni 30° C) tolmu, toiduainete ja vedelike ning kuumuse ja valguse eest kaitstult.
English: • Pull off the Outer Needle Shield.
Estonian: • Tõmmake nõela väliskork otse ära.
English: Liprolog Mix25 100 units/ml suspension for injection is a white, sterile suspension and contains 100 units of insulin lispro in each millilitre (100 units/ml) suspension for injection.
Estonian: Kuidas Liprolog 100 ühikut/ml süstesuspensioon kolbampullis välja näeb ja pakendi sisu Liprolog Mix25 100 ühikut/ml süstesuspensioon on valge, steriilne suspensioon ja sisaldab 100 toimeühikut lispro-insuliini igas milliliitris (100 ühikut/ml) süstesuspensioonina.
English: Store in a refrigerator (2°C - 8°C).
Estonian: Hoida külmkapis (2 C - 8 C juures).
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Liprolog 100 units/ml solution for injection in cartridge Insulin lispro
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE Liprolog 100 ühikut/ml süstelahus kolbampullis Lispro-insuliin
English: - Dose Knob:
Estonian: - Süstimisnupp:
English: • You must only use Liprolog cartridges in Lilly insulin pens or the BerliPen® areo 3.
Estonian: • Te tohite Liprolog kolbampulle kasutada ainult Lilly insuliini pen-süstlites ja BerliPen® areo 3-ga. Veenduge, et teie pen-süstliga kaasasoleval infolehel on nimetatud Liprolog või Lilly kolbampulle.
English: Burgundy
Estonian: Veinipunane
English: France TEVA SANTE Le Palatin 1
Estonian: TEVA SANTE Le Palatin 1
English: Portugal Ciclum Farma Unipessoal, Lda.
Estonian: Ciclum Farma Unipessoal, Lda.
English: Belgium Eurogenerics NV Heizel Esplanade b22 1020 Brussel
Estonian: Eurogenerics NV Heizel Esplanade b22 1020 Brussel Belgium
English: 1 cours du Triangle 92936 Paris la Défense Cedex France
Estonian: 1 cours du Triangle 92936 Paris la Défense Cedex
English: Norway Teva Sweden AB Järnvägsgatan 11, Box 1070, 251 10 Helsingborg Sweden
Estonian: Teva Sweden AB Järnvägsgatan 11, Box 1070, 251 10 Helsingborg Sweden
English: Radlická 3185/1c 150 00 Prague
Estonian: Radlická 3185/1c
English: DK-2300 Köpenhamn S, Denmark
Estonian: DK-2300 Copenhagen S, Denmark
English: Bratislava 821 02
Estonian: Bratislava 821 02 Slovak Republic
English: Belgium Sandoz NV/SA Telecom Gardens Medialaan 40
Estonian: Sandoz NV/SA Telecom Gardens Medialaan 40
English: U Nákladového nádraží 10 CZ-130 00, Praha 3, Czech Republic
Estonian: CZ-130 00, Praha 3, Czech Republic
English: Denmark Teva Denmark A/S, Parallelvej 10-12, DK-2800 Kongens Lyngby, Denmark
Estonian: Teva Denmark A/S, Parallelvej 10-12, DK-2800 Kongens Lyngby, Denmark
English: Poland Teva Pharmaceuticals Polska Sp. z o.o.
Estonian: Teva Pharmaceuticals Polska Sp. z o.o.
English: Poland Sandoz GmbH Biochemiestrasse 10 Kundl, A-6250
Estonian: Sandoz GmbH Biochemiestrasse 10 Kundl, A-6250
English: Germany Aliud Pharma GmbH Gottlieb-Daimler-Str. 19
Estonian: Aliud Pharma GmbH Gottlieb-Daimler-Str.
English: Germany HEXAL Aktiengesellschaft Industriestr.
Estonian: Aktiengesellschaft Industriestr.
English: B-Vilvoorde
Estonian: B-Vilvoorde Belgium
English: TEVA Pharmaceuticals Slovakia s.r.o.
Estonian: Pharmaceuticals Slovakia s.r.o.
English: 15 N.V Gogol Str. Sofia
Estonian: Teva Pharmaceuticals Bulgaria EOOD 15 N.V Gogol Str. Sofia
English: Verovškova 57 SI1000 Ljubljana
Estonian: Verovškova 57 SI1000 Ljubljana Slovėnia
English: Latvia Sandoz d.d., Verovškova 57, SI-1000 Ljubljana,
Estonian: Sandoz d.d., Verovškova 57, SI1000 Ljubljana, Slovenia
English: Bad Vilbel D-61118
Estonian: Stadastrasse 2-18 Bad Vilbel D-61118 Germany
English: Teva Pharmaceuticals CR s.r.o.
Estonian: Czech Republic Teva Pharmaceuticals CR s.r.o.
English: Portugal Pharmaceutical Works Polpharma S.A.
Estonian: Pharmaceutical Works Polpharma S.A.
English: Sweden Sandoz A/S, , Edvard Thomsens Vej 14
Estonian: Sandoz A/S, Edvard Thomsens Vej
English: 00-113 Warszawa
Estonian: Emilii Plater 53 00-113 Warszawa Poland
English: Finland Sandoz A/S Edvard Thomsens Vej 14 Copenhagen S 2300 Denmark
Estonian: Sandoz A/S Edvard Thomsens Vej 14 Copenhagen S 2300 Denmark
English: Quinta da Fonte, Rua Vitor Câmara, 2 - Edifício D.
Estonian: Quinta da Fonte, Rua Vitor Câmara, 2Edifício D. Amélia, Piso 1, Ala B 2770-229 Paço de Arcos
English: Latvia Teva Pharma B.V., Computerweg 10, 3542DR Utrecht, The Netherlands
Estonian: Teva Pharma B.V., Computerweg 10, 3542DR Utrecht, the Netherlands
English: Finland ratiopharm GmbH Graf-Arco-Strasse 3
Estonian: Soome ratiopharm GmbH Graf-Arco-Strasse 3 Ulm 89079
English: Norway Sandoz A/S, Edvard Thomsens Vej 14, 2300 København S,
Estonian: Sandoz A/S, Edvard Thomsens Vej 14, 2300 København S,
English: Estonia Sandoz d.d.
Estonian: Sandoz d.d.
English: Slovenia
Estonian: Slovakkia
English: The
Estonian: TEVA
English: France SANDOZ 49, avenue Georges Pompidou 92300 Levallois-Perret France
Estonian: 49, avenue Georges Pompidou
English: 92517 Boulogne Billancourt Cedex
Estonian: EG LABOLaboratoires EuroGenerics "Le Quintet"bâtiment A 12, rue Danjou 92517 Boulogne Billancourt Cedex France
English: Germany ratiopharm GmbH Graf-Arco-Str. 3
Estonian: Saksamaa ratiopharm GmbH Graf-Arco-Str. 3 D-89079 Ulm Germany
English: 19, Pelplinska street 83-200 Starogard Gdanski Poland
Estonian: 19, Pelplinska street 83-200 Starogard Gdanski
English: Teva UK Limited, Brampton Road, Hampden Park, Eastbourne, East Sussex BN22 9AG United Kingdom
Estonian: Ühendkuningriik Teva UK Limited, Brampton Road,
English: Finland Stada Arzneimittel AG Stadastrasse 2 - 18
Estonian: Stada Arzneimittel AG Stadastrasse 2 - 18 Bad Vilbel 61118
English: Pelplinska Street,
Estonian: Hampden Park,
English: Orlistat STADA 120 mg
Estonian: Orlistat STADA 120 mg 120 mg
English: Lithuania Pharmaceutical Works POLPHARMA S.A., 19 Pelplinska Street, Starogard Gdanski 83-200 Poland
Estonian: Pharmaceutical Works POLPHARMA S.A., 19 Pelplinska Street, Starogard Gdanski 83200 Poland
English: Latvia Pharmaceutical Works POLPHARMA SA, 19 Pelplińska Street, 83-200 Starogard Gdański, Poland
Estonian: Pharmaceutical Works POLPHARMA SA, 19 Pelplińska Street, 83-200 Starogard Gdański, Poland
English: 19, Peplinska Street Starogar Gdanski
Estonian: Pharmaceutical Works Polpharma S.A 19, Peplinska Street Starogar Gdanski
English: Orlistat Polpharma 60 mg
Estonian: Orlistat Polpharma 60 mg 60 mg
English: Estonia Teva Pharma B.V. Computerweg 10
Estonian: Teva Pharma B.V.
English: Poland Pharmaceutical Works POLPHARMA SA 19, Pelplińska Street 83-200 Starogard Gdański Poland
Estonian: Pharmaceutical Works POLPHARMA SA 19, Pelplińska Street 83-200 Starogard Gdański
English: Urorec silodosin
Estonian: Urorec silodosiin
English: What measures are being taken to ensure the safe and effective use of Urorec?
Estonian: Mis meetmed võetakse, et tagada Uroreci ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Urorec on 29 January 2010.
Estonian: Euroopa Komisjon andis Uroreci müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 29. jaanuaril
English: The full EPAR for Urorec can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Uroreci kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Urorec is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Uroreci võimalikult ohutu kasutamine.
English: Other information about Urorec
Estonian: Muu teave Uroreci kohta
English: They should be swallowed whole, preferably with a glass of water.
Estonian: Need tuleb alla neelata tervelt, soovitatavalt koos klaasi veega.
English: The most common side effect with Urorec (seen in more than 1 patient in 10) is a reduction in the amount of semen released during ejaculation.
Estonian: Uroreci kõige sagedam kõrvalnäht (esinenud enam kui 1 patsiendil 10st) on seemnevedeliku hulga vähenemine seemnepurskel.
English: The CHMP decided that Urorec's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Uroreci kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Urorec is a medicine that contains the active substance silodosin.
Estonian: Urorec on ravim, mis sisaldab toimeainena silodosiini.
English: In addition, the company that makes Urorec will ensure that eye surgeons are provided with information on IFIS in all Member States where the medicine will be marketed.
Estonian: Lisaks peab Uroreci tootja tagama, et silmakirurgidele Euroopa Liidu liikmesriikides, kus ravimit turustatakse, antakse teavet lõdva iirise sündroomist.
English: Why has Urorec been approved?
Estonian: Miks Urorec heaks kiideti?
English: In the two studies where Urorec was compared only with placebo, the IPSS was around 21 points at the start of the study.
Estonian: Kahes uuringus, milles Uroreci võrreldi ainult platseeboga, oli rahvusvaheline eesnäärme sümptomite skoor uuringu alguses ümardatuna 21 punkti.
English: For more information about treatment with Urorec, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Uroreciga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The active substance in Urorec, silodosin, is an alpha adrenoreceptor antagonist.
Estonian: Uroreci toimeaine silodosiin on alfa-adrenoretseptorite antagonist.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Urorec, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Uroreci omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: What is Urorec?
Estonian: Mis on Urorec?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Urorec.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: This is a summary of the European public assessment report (EPAR) for Urorec.
Estonian: See on ravimi Urorec Euroopa avaliku hindamisaruande kokkuvõte.
English: For the full list of all side effects and restrictions with Urorec, see the package leaflet.
Estonian: Uroreci kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: What is the risk associated with Urorec?
Estonian: Mis riskid Uroreciga kaasnevad?
English: In the third study, IPSS was around 19 points before treatment, falling by 7.0 points in the men who took Urorec after 12 weeks, 6.7 points in the men who took tamsulosin and 4.7 points in the men who took placebo.
Estonian: Pärast 12-nädalast ravi vähenes see Uroreci võtnud meestel 7,0 punkti võrra, tamsulosiini võtnud meestel 6,7 punkti võrra ja platseebot võtnud meestel 4,7 punkti võrra.
English: After 12 weeks, it had fallen by around 6.4 points in the men who took Urorec, and by around 3.5 points in the men who took placebo.
Estonian: Pärast 12nädalast ravi oli see Uroreci võtnud meestel vähenenud ligikaudu 6,4 punkti võrra ja platseebot võtnud meestel ligikaudu 3,5 punkti võrra.
English: What benefit has Urorec shown during the studies?
Estonian: Milles seisneb uuringute põhjal Uroreci kasulikkus?
English: One of these studies also compared Urorec with tamsulosin (another medicine used for BPH).
Estonian: Ühes neist uuringutest võrreldi Uroreci ka tamsulosiiniga (samuti eesnäärme healoomulise hüperplaasia ravim).
English: Urorec is not recommended for patients with severe kidney problems.
Estonian: Raskete neeruprobleemidega patsientidel ei soovitata Uroreci kasutada.
English: The effects of Urorec were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Uroreci toimet muude katsetega.
English: Urorec is used to treat the symptoms of benign prostatic hyperplasia (BPH, an enlarged prostate gland) in adults.
Estonian: Uroreci kasutatakse eesnäärme healoomulise hüperplaasia (suurenemise) sümptomite raviks täiskasvanutel.
English: Urorec has been compared with placebo (a dummy treatment) in three main studies involving over 1,800 men with BPH.
Estonian: Uroreci uuriti kolmes põhiuuringus, kus osales enam kui 1800 eesnäärme healoomulise hüperplaasiaga meest.
English: How is Urorec used?
Estonian: Kuidas Uroreci kasutatakse?
English: How does Urorec work?
Estonian: Kuidas Urorec toimib?
English: What is Urorec used for?
Estonian: Milleks Uroreci kasutatakse?
English: It works by blocking receptors called alpha1A adrenoreceptors in the prostate gland, the bladder and the urethra (the tube that leads from the bladder to the outside of the body).
Estonian: Urorec blokeerib eesnäärmes, kusepõies ja kusitis (juha, mille kaudu uriin kusepõiest väljutatakse) leiduvad alfa-1Aadrenoretseptorid.
English: Urorec was more effective than placebo and as effective as tamsulosin at reducing symptoms of BPH.
Estonian: Urorec oli eesnäärme healoomulise hüperplaasia sümptomite vähendamisel efektiivsem kui platseebo ja sama efektiivne kui tamsulosiin.
English: The medicine can only be obtained with a prescription.
Estonian: Urorec on retseptiravim.
English: How has Urorec been studied?
Estonian: Kuidas Uroreci uuriti?
English: Infiltration
Estonian: Infiltratsioon
English: Local or regional injection intra-oral Submucosal use
Estonian: Lokaalne või regionaalne intraoraalne süste Submukosaalne
English: John Tsaprazis SA 157 Michalakopoulou Str.
Estonian: John Tsaprazis SA 157 Michalakopoulou Str. 11527, Athens Greece
English: Septodont GmbH Felix-Wankel-Str. 9 D - 53859
Estonian: Septodont GmbH Felix-Wankel-Str. 9 D - 53859 NiederkasselMondorf
English: Dental use Infiltration and perineural use in the oral cavity
Estonian: Dentaalne Infiltratsioon ja perineuraalne kasutamine kasutamine suuõõnes
English: 40 mg/ml + 5 microg/ml
Estonian: 40 mg/ml + 5 micro/ml
English: Epinephrine 0.01 mg/ml
Estonian: Epinefriin 0,01 mg/ml
English: Submucosal use Infiltration and perineural use
Estonian: Submukosaalne Infiltratsioon ja perineuraalne kasutamine
English: Luxembourg Septodont Nv-Sa 87 Avenue de la Constitution
Estonian: Luksemburg Septodont Nv-Sa 87 Avenue de la Constitution B-1083 Brussel
English: Dental use Submucosal use
Estonian: Dentaalne Submukosaalne
English: Septanest Z Adrenaliną
Estonian: Septanest Cu Adrenalină
English: Adrenaline 10 microg/ml
Estonian: Adrenaliin 10 µg/ml
English: Infiltration Periodontal use
Estonian: Infiltratsioon Peridontaalne
English: 40 mg/0,01 mg v 1 ml raztopina za injiciranje
Estonian: Septanestepi 40 mg/0,01 mg v 1 ml raztopina za injiciranje
English: Adrenaline 5 microg/ml
Estonian: Adrenaliin 5 µg/ml
English: Belgium Septodont Nv-Sa 87 Avenue de la Constitution
Estonian: Septodont Nv-Sa 87 Avenue de la Constitution B-1083 Brussel Belgium
English: 94107 Saint-Maur-desFossés Cedex France
Estonian: 58, rue du Pont de Créteil 94107 Saint-Maur-DesFossés Cedex France
English: Submucosal use Articaine hydrochloride 40 mg/ml
Estonian: Submukosaalne Artikaiinvesinikkloriid 40 mg/ml
English: Septanest s adrenalinem 1:100 000
Estonian: Septanest Z Adrenaliną 1: 100
English: Adrenaline 0.005 mg/ml adrénaline (tartrate d'): non précisé
Estonian: 0,005 mg/ml adrenaliintartraadina : pole täpsustatud
English: Septanest s adrenalinem 1:200 000
Estonian: Septanest Z Adrenaliną 1: 200
English: Germany Septodont GmbH Felix-Wankel-Str. 9
Estonian: Septodont GmbH Felix-Wankel-Str. 9 D-53859 Niederkassel Germany
English: Adrenaline 0.01 mg/ml adrénaline (tartrate d'): non précisé
Estonian: 0,01 mg/ml adrenaliintartraadina : pole täpsustatud
English: Spécialités Septodont 58 rue du Pont de Créteil
Estonian: Spécialités Septodont 58 rue du Pont de Créteil 94100 Saint-Maur-desFossés
English: 58, rue du Pont de Créteil
Estonian: 58, rue du Pont de Créteil 94100 Saint-Maur-desFossés
English: 40 mg/ml + 10 microg/ml
Estonian: Septocaine Forte 40 mg/ml + 10 micro/ml
English: Articaína, cloridrato 40 mg/ml
Estonian: Oromukosaalne Artikaiinvesinikkloriid 40 mg/ml
English: Septanest 1/100 000 68 mg/1.7 ml + 0.031 mg/1.7 ml
Estonian: Septanest Forte 40 mg/ml + 0.01 mg/ml
English: Septanest mit Epinephrin 1:100.00040 mg/ml + 0,01 mg/ml
Estonian: Septanest Forte 40 mg/ml + 0,01 mg/ml
English: Septodont SAS 58, rue du Pont de Créteil
Estonian: Specialites Septodont 58, rue du Pont de Créteil 94100 Saint-Maur-desFossés
English: Not Known (cannot be estimated from the available data)
Estonian: Teadmata (ei saa hinnata olemasolevate andmete alusel)
English: b.Antimalarials were allowed.
Estonian: b.Malaariaravimid olid lubatud.
English: 3 Parallel arms:
Estonian: 3 paralleel-rühma:
English: Possible serious side effects In rare cases, infection may be life-threatening
Estonian: Võimalikud tõsised kõrvaltoimed Harvadel juhtudel võivad infektsioonid olla eluohtlikud.
English: c OPAL BEYOND had a duration of 6 months.
Estonian: OPAL BEYOND kestis 6 kuud.
English: Treatment groups (Randomisation ratio)
Estonian: Ravirühmad (randomiseerimise suhe)
English: You can take XELJANZ with or without food.
Estonian: Te võite XELJANZi võtta nii koos toiduga või ilma.
English: ALC greater than or equal to 750
Estonian: ALC on suurem kui või võrdne 750ga
English: If you take more XELJANZ than you should If you take more tablets than you should, immediately tell your doctor or pharmacist.
Estonian: Kui te võtate XELJANZi rohkem kui ette nähtud Kui te võtate rohkem tablette kui ette nähtud, rääkige sellest viivitamatult oma arstile või apteekrile.
English: These changes generally resolved within 2-6 weeks after discontinuation of treatment.
Estonian: Need muudatused kadusid reeglina 2...6 nädalat pärast ravi algust.
English: The safety and efficacy of tofacitinib in children aged 0 to less than 18 years have not been established.
Estonian: Lapsed Tofatsitiniibi ohutus ja efektiivsus lastel vanuses 0 kuni alla 18 aastat ei ole tõestatud.
English: Time to Treatment Failure in Maintenance Study OCTAVE Sustain (Kaplan-Meier Curves)
Estonian: Aeg ravi ebaõnnestumiseni säilitusravi uuringus OCTAVE Sustain (Kaplani-Meieri kõverad)
English: Store in the original, bottle and/or blister, in order to protect from moisture.
Estonian: Hoida originaalpudelis ja/või -blistris, niiskuse eest kaitstult.
English: Study III (ORAL Standard)
Estonian: Uuring III (ORAL Standard)
English: Study VII (ORAL Strategy)
Estonian: Uuring VII (ORAL Strategy)
English: (E171), macrogol 3350, and triacetin (E1518).
Estonian: makrogool 3350 ja triatsetiin (E1518).
English: Month 6: mTSS ACR70
Estonian: 6. kuu: mTSS ACR70
English: UNIQUE IDENTIFIER-2D BARCODE 2D barcode carrying the unique identifier included.
Estonian: AINULAADNE IDENTIFIKAATOR - 2D-vöötkood Lisatud on 2D-vöötkood, mis sisaldab ainulaadset identifikaatorit.
English: If any serious allergic or anaphylactic reaction occurs, tofacitinib should be discontinued immediately.
Estonian: Raskete allergiliste või anafülaktiliste reaktsioonide tekkimisel tuleb tofatsitiniibravi kohe katkestada.
English: Study V (ORAL Step)
Estonian: Uuring V (ORAL Step)
English: Tofacitinib binds predominantly to albumin and does not appear to bind to α1-acid glycoprotein.
Estonian: Tofatsitiniib seondub peamiselt albumiiniga ega näi seonduvat α1-happe glükoproteiiniga.
English: • antibiotics such as clarithromycin and rifampicin, used to treat bacterial infections
Estonian: • antibiootikumid, nt klaritromütsiin ja rifampitsiin, millega ravitakse bakteriaalseid infektsioone
English: As described in Tables 1, 2 and 3 below, recommendations for temporary dose interruption or permanent discontinuation of treatment are made according to the severity of laboratory abnormalities (see section 4.4).
Estonian: Nagu kirjeldatud alltoodud tabelites 1, 2 ja 3, sõltuvad manustamise ajutise katkestamise või täieliku lõpetamise soovitused laboratoorsete analüüside kõrvalekallete tõsidusest (vt lõik 4.4).
English: • Patients with an ALC less than 1,000 cells/mm3 (see section 4.2).
Estonian: • patsiendid, kelle ALC on alla 1000 raku mm3 kohta (vt lõik 4.2);